進口代理─以色列─「CARMEL DIAGNOSTICS」非侵入性胚胎篩選系統

Carmel Diagnostics成功開發並專利一種創新的非侵入性胚胎篩選系統，針對試管嬰兒市場，胚胎可行性評估能夠實現單胚胎移植，顯著降低多胎的風險，通過減少每個IVF週期中轉移的前胚胎數量。

Fertissimo TCL分析儀於2019年10月獲得CE標記 ，在歐洲已成功進行了數百個胚胎的臨床試驗（並且醫療界對該設備反應良好，更多試驗正在完成中） 

我們系統的關鍵利益相關者包括患者、試管嬰兒診所、醫生、醫療管理機構和醫療保險公司 ，Carmel Diagnostics擁有強大且成熟的管理團隊，在婦科領域擁有豐富的經驗。

Carmel Diagnostics has successfully developed and patented an innovative noninvasive embryo selection system for the IVF market 

Embryo viability assessment enabling Single Embryo Transfer that significantly reduces the risk of multiple births, by decreasing the number of transferred pre embryos per cycle of IVF 

The Fertissimo TCL Analyzer obtained CE Mark in October 2019. Successful clinical trials testing hundreds of embryos have been performed in Europe ( and the device has been well received by the medical community, with more trials pending completion 

Key stakeholders for our system include patients, IVF Clinics, physicians, healthcare authorities, and medical insurance companies.

Carmel Diagnostics has a strong and established management team with significant experience in the gynecological sector